68Ga-DOTA-TATE PET-CT comparison with 99mTc-HYNIC-TOC SPECT-CT in the assessment of the extent of the disease in patients with malignant endocrine tumors: our experience (preliminary results) Abstract #115

Introduction: In neuroendocrine tumors (NETs), the workup is often difficult not only to visualize but also to co-localize the lesions anatomically. Liver and bones are one of the most frequent sites of metastases in patients with endocrine tumors. The Tyr3-octreotate (TATE) somatostatin analogue differs from TOC in that the terminal threonine replaces threoninol. The terminal threonine results in a higher receptor binding (mainly subtype 2) and better internalisation, with the consequence that tumor uptake of the tracer is intense.
Aim(s): To evaluate the diagnostic value of 68Ga-DOTA-TATE PET-CT comparison with 99mTc-HYNIC-TOC SPECT-CT in the assessment of disease extent in patients with malignant neuroendocrine tumors in our institution.
Materials and methods: 68Ga-DOTA-TATE PET-CT and 99mTc-HYNIC-TOC SPECT/CT studies were performed in nine patients. The interval time between of these two studies was 2 – 28 weeks. Conventional scintigraphy was acquired on the hybrid gamma camera SPECT/CT in 2-4 h after intravenous injection of 99mTc-HYNIC-TOC. The injected activity was 550-740 MBq (15-20mCi). The following views were gathered: planar AP, PA and SPECT/CT of the chest and abdomen. PET-CT scans were acquired 45 – 60 min postinjection of 120 – 200 MBq (3.5 – 5.5 mCi) of 68Ga-DOTA-TATE. Data acquisition was performed with a 15-cm axial field of view (FOV) and 55-cm transaxial FOV PET-CT scanner. Patients were imaged in 3-dimensional mode with the duration of acquisition 3 - 5 min per bed position in emission mode.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Norbert Szalus

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2879 Lung Neuroendocrine Tumors: Experience of Medical Oncology Department of Hospital 1st November 1954 Oran
Introduction: Lung neuroendocrine tumors account for 25% of all neuroendocrine tumors. It is a heterogeneous group that meets morphological criteria; immunohistochemical and molecular; defining 4 groups: Typical and atypical carcinoid tumors, neuroendocrine carcinomas with large cell and small cells. Carcinoid syndrome is rare in these tumors and the treatment is based on surgery for localized forms and multimodal treatment for metastatic forms.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Hakima Kehili
#2764 Cystic Pancreatic Neuroendocrine Tumors. Can We Diagnose Them Preoperatively?
Introduction: Pancreatic neueroendocrine tumors rarely undergo cystic changes but they are often misdiagnosed as pancreatic mucinous cystadenoma, mucinous cystadenocarcinoma, serous cystadenoma, and solid and cystic papillary tumors, or pseudocyst.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2816 Germline Variants in Cancer Predisposing Genes in Young Adults with Neuroendocrine Tumors
Introduction: Advances in genomics have enabled the recognition of new cancer predisposing genes (CPG). There are few studies of CPG in neuroendocrine tumors (NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Prof Rachel Riechelmann
#2986 Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data
Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare and heterogeneous neoplasms with a 10-year survival rate less than 30%. Up to 43% of them are driven by inactivating mutations in ATRX or DAXX. These are important players at chromatin remodeling, that when mutated prone cancer cells to initiate the alternative lengthening of telomeres (ALT). ALT phenotype correlates with in situ loss of expression of the proteins ATRX or DAXX and can be corroborated by telomere-FISH.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: DVM Tiago B Gaspar